Globalization of clinical trials in oncology : a worldwide quantitative analysis

Article indépendant

IZARN, F. | HENRY, J. | BESLE, S. | RAY-COQUARD, I. | BLAY, J.-Y. | ALLIGNET, B.

BACKGROUND: Over the past two decades, the globalization of oncology clinical trials has expanded, yet significant disparities persist across countries. This study aimed to evaluate these geographical inequalities, the evolution of trial phases, and the adherence to ethical standards according to the World Bank's income group. MATERIALS AND METHODS: The ClinicalTrials.gov database was searched and recorded in June 2024. We analyzed data from 87 748 oncology clinical trials conducted between 2000 and 2021, across high-income (HICs), upper-middle-income (UMICs), lower-middle-income (LMICs), and low-income countries. Key metrics included trial density, funding sources, registration timing, and trial phase distribution. RESULTS: The number of oncology trials increased significantly, with a mean absolute annual rise of 266.6 trials, with China currently being the leading site of early- and validation-phase trials. While HICs still present the highest trial densities, UMICs showed a notable increase in early-phase trials, reflecting a shift in research dynamics. However, despite these advances, 76.4% of countries still had no new trials initiated by 2024. Additionally, ethical practices saw improvement from 2005 to 2021 with an increase in pre-commencement registration (from 9.2% to 58%, P < 0.0001), and more validation-phase trials with a survival variable as the primary outcome (from 40% to 59.6%, P < 0.0001). CONCLUSIONS: Despite the growth in oncology clinical trials, significant disparities in trial distribution and access remain, especially in LMICs. Continued investments in research infrastructure and adherence to ethical standards are crucial to ensure that clinical research benefits are equitably distributed, particularly in regions with the greatest need for advanced cancer therapies.

http://dx.doi.org/10.1016/j.esmoop.2024.104086

Voir la revue «ESMO open, 10»

Autres numéros de la revue «ESMO open»

Consulter en ligne

Suggestions

Du même auteur

Globalization of clinical trials in oncology ...

Article | IZARN, F. | ESMO open | n°1 | vol.10

BACKGROUND: Over the past two decades, the globalization of oncology clinical trials has expanded, yet significant disparities persist across countries. This study aimed to evaluate these geographical inequalities, the evolution o...

Fin de vie et temps ultime : qu'en disent les...

Article | CHAZOT, Isabelle | Éthique & Santé | n°3 | vol.13

A partir de la question "D'après vous, docteur, j'en ai pour combien de temps ?", prononcée par les malades parvenus en fin de vie, les auteurs ont examiné ce temps en conduisant des entretiens auprès de patients hospitalisés en u...

Fin de vie et temps ultime : qu'en disent les...

Article indépendant | CHAZOT, Isabelle | Éthique & Santé | n°3 | vol.13

A partir de la question "D'après vous, docteur, j'en ai pour combien de temps ?", prononcée par les malades parvenus en fin de vie, les auteurs ont examiné ce temps en conduisant des entretiens auprès de patients hospitalisés en u...

De la même série

Globalization of clinical trials in oncology ...

Article indépendant | IZARN, F. | ESMO open | n°1 | vol.10

BACKGROUND: Over the past two decades, the globalization of oncology clinical trials has expanded, yet significant disparities persist across countries. This study aimed to evaluate these geographical inequalities, the evolution o...

A taxonomy of the factors contributing to the...

Article indépendant | CHERNY, N. I. | ESMO open | n°1 | vol.10

Many patients with cancer approaching the end of life (EOL) continue to receive treatments that are unlikely to provide meaningful clinical benefit, potentially causing more harm than good. This is called overtreatment at the EOL....

Health networking on cancer in the European U...

Article indépendant | CASALI, P. G. | ESMO open | n°2 | vol.10

Health networking is in principle a formidable instrument to address many challenges posed by cancer, one of the two most common and most lethal non-communicable chronic diseases. The European Union (EU)'s Beating Cancer Plan fore...

Quality-of-care indicators for oncology manag...

Article indépendant | KANESVARAN, R. | ESMO open | n°3 | vol.10

Cancer is a major cause of morbidity and mortality, with variable outcomes seen in the Asia-Pacific region due to substantial differences in cancer care and management. Quality indicators are evidence-based, standardized measures ...

Practical cancer nutrition, from guidelines t...

Article indépendant | HUSTAD, K. S. | ESMO open | n°4 | vol.10

BACKGROUND: Malnutrition affects 20%-70% of cancer patients, depending on tumour type, disease stage, and clinical setting. While nutritional care is essential for improving patients' quality of life and clinical outcomes, it is n...

Chargement des enrichissements...